Videos

“The cost and the burden of being able to find permissions and licenses within different states to continue to offer these services once the waivers end will essentially negate all of these services,” says Kara L. Watts, MD.

“Patients are paying humongous amounts of money to get pills that are essentially very, very, very cheap,” says Faysal A. Yafi, MD, FRCSC.

"After 6 months, about 77% of this group have more than 50% improvement on their main symptom," says John Heesakkers, MD, PhD.

“I think there's a mindset out there that you have to have experienced a particular mental health crisis or some other major sort of breaking point event in your medical career. That's not actually my story,” says Colin P. West, MD, PhD.

“Remote supervision is something that we are utilizing now and look forward to even growing further,” says Lisa J. Finkelstein, DO, FACOS.

“I would classify hidden burdens as things which we don't appreciate on the surface, or that aren't obvious that are associated with erectile dysfunction,” says John J. Mulcahy, MD, PhD.

"The hazard ratio was 0.42, which is a 58% reduction of an MFS event in favor of the combination arm," says Neal D. Shore, MD, FACS.

"We found that in the 25-patient pilot study that we did, that the accuracy was about 98% of what a standard sequencer would offer," says Deepak Kapoor, MD.

The update was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

"Among the 76 men–who had an average age of about 70 and a PSA value of 4.4–up to 99% of them were able to find recurrent cancers," says Brian Helfand, MD, PhD.

"What we noticed is that even though it's not in the NCCN guidelines, a lot of urologists are using oral Relugolix in combination with other prostate cancer medications in similar numbers to the injectables," says Jason M. Hafron, MD.

"Something that we did find that was more promising was that regardless of whether a patient did or did not have a mental health disorder diagnosis, that did not affect their rate of receiving gender-affirming medical therapy," says Helen Sun, MD.

"We found that on average, [a] patient went into surgery with a GFR of about 55, and came out with a GFR of about 44," says Steven Campbell, MD, PhD.

"Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer," says Eric Li, MD.

“I think we really hit upon how we work closely together in renal cell cancer—urothelial cancers in particular,” says Joelle Hamilton, MD.

“For a lot of settings, a lot of patients, and in a lot of domains within urology, audio visits are equivalent in terms of satisfaction and outcomes to video visits,” says Kara L. Watts, MD.

Roger Li, MD, highlights 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting.

"Not only do we lose patients and we lose this opportunity to actually take good care of them, but it actually undermines their trust in us as a profession," says A. Lenore Ackerman, MD, PhD.

“It's pretty apparent that if physicians are not going to be reimbursed properly for telehealth, they're not going to use utilize it,” says Lisa J. Finkelstein, DO, FACOS.

“I think being savvy about how you deal with BCG supply on the administrative side is important,” says Suzanne B. Merrill, MD, FACS.

“Allowing the waiver to continue indefinitely would be a tremendous win for telehealth for both sides, the patients and the health care providers,” says Kara L. Watts, MD.

Scott T. Tagawa, MD, discusses trials exploring 177Lu-PSMA-617 in settings earlier than it’s FDA-approved indication for patients with heavily pretreated metastatic castration-resistant prostate cancer.

Melissa A. Laudano, MD, highlights 3 studies in overactive bladder/incontinence being presented at the 2023 American Urological Association Annual Meeting.

Helen L. Bernie, DO, MPH, highlights 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting.

“In terms of next steps, we are collaborating with other institutions…to see how our model performs in their patient populations,” says Eric Li, MD.

Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.

"In the periods where BCG utilization dropped, we saw a concomitant increase in mitomycin C," says Brian Chun, MD.

“He’s had just such a huge impact for me as a role model, a teacher, a wonderful support system, just such a kind-hearted person,” says Stacy Loeb, MD, MSc, PhD (hon).

“Waiting for others to fix health care is not a good strategy. Instead, be determined to begin your journey to your mountaintop of joy and fulfillment,” says Scott A. MacDiarmid, MD, FRCPSC.